Agios Pharmaceuticals (AGIO) Stock Price, Quote & News

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pedi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 649 8600

Website: www.agios.com

Address:

88 Sidney Street, Cambridge, United States

Dkll303 May. 15 at 5:24 PM

$CADL fidelity will sell this on a heart beat , they did at $CHRS , they did at $AGIO …they aren’t Blackrock or wellington , ya , where is wellington mgmt , ???( they know better , tAK is no ceo material ) You are clearly , without deep pocket friends , hahah @telomerase

0 · Reply

Dkll303 May. 13 at 7:51 PM

$AGIO Morgan Stanley .ya get all the insiders out yet , for this qtr end ? Imagine selling as you put in an FDA approval request for SCD So, you know these misfits haven’t got the goods , and they know it …so they sell Losers for 8 years running now ! Negative 45% ROI with FOUSE on the property , or is she fcuking up Cape Cod with her coastal mgmt desires !!! She is not on Sydney st !!!

0 · Reply

freddie04 May. 12 at 6:05 PM

$AGIO neither one , can create value and the cash is being burned up

0 · Reply

freddie04 May. 12 at 6:04 PM

$AGIO 5 year return from Fouse NEGATIVE 49% …Jackie Fouse is a failure With Brian Goff , right behind her failing as well !!! 2 biotech losers

0 · Reply

freddie04 May. 12 at 5:06 PM

$AGIO No money to carry the news to the PRNEWSWIRE, haha Chris Bowben’s Mitapivat .., once again , submitted Sarah G , their welfare employee , living off options and Chris B. , hasn’t come up with any new discoveries on her reign here Just a huge sucking sound from Chris Bowden and his successes All senior execs here are mere pawns , no brains , no value created in 8 years !!! Congrats Fouse , Goff, Sarah and Milanova

0 · Reply

Dkll303 May. 11 at 6:27 PM

$AGIO yes Morgan Stanley facilitated the LOSERS at AGIOS to unload their options today ..they shorted the stock at $29 , knowing …NO ONE WILL BUY THIS STOCK WITH THE: SLOB-SEY TWINS THERE …..FOISE AND GOOF BALL GOFF The street knows they are both washed up executives, where they fcuked up at other companies they came from !!! Then the parade of the rest

0 · Reply

Dkll303 May. 11 at 2:22 PM

$AGIO back at it again, huh Morgan Stanley !!! Pushing it for the inside …SELLERS

0 · Reply

Dkll303 May. 7 at 11:40 AM

$AGIO Wake up losers at Agios , get something done , don’t rely on Morgan Stanley to run it so your options are GREEN . Goff , a fcukin goof ball, Fouse , down on fcuking up the Cape in Mass with coastal mgmt . Fouse your coasting at AGIOS , you might create a second low of yours at $16.95 ..hip hip hoorah , for the losers , the welfare executives, sucking down from 1.8 billion and NOTHING !!!

0 · Reply

Dkll303 May. 6 at 5:15 PM

$AGIO Morgan Stanley wants their run for the useless biotech misfits , who will selll in the next 30 days , to be worth their while to run it for Fouse Useless Goff Lack of knowledge Sarah No marketing by Milanova Pathetic Krishnan Line the misfits of agios And MS will create value for the galaxtilly pathetic executives, that suck a salary out here They all got nothing and create even less

0 · Reply

Dkll303 May. 6 at 5:09 PM

$AGIO misfits still exist here

0 · Reply

Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat

2026-05-12T19:15:22.000Z - 2 days ago

Agios Pharmaceuticals to present mitapivat data at EHA Congress

May 12, 2026, 9:31 AM EDT - 3 days ago

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

May 12, 2026, 9:30 AM EDT - 3 days ago

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

2026-04-30T12:15:00.000Z - 15 days ago

Agios Pharmaceuticals price target lowered to $36 from $39 at Truist

Apr 29, 2026, 8:00 AM EDT - 16 days ago

Agios Pharmaceuticals Earnings Call Transcript: Q1 2026

2026-04-29T11:02:17.000Z - 16 days ago

Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)

Apr 29, 2026, 6:30 AM EDT - 16 days ago

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

2026-04-21T12:54:10.000Z - 24 days ago

Agios Pharmaceuticals price target lowered to $41 from $44 at BofA

NVO

2026-04-20T16:11:17.000Z - 25 days ago

H.C. Wainwright cuts Agios target on smaller market post Novo data

NVO

2026-04-20T16:00:43.000Z - 25 days ago

Agios Pharmaceuticals falls -23.4%

2026-04-20T15:09:57.000Z - 25 days ago

Agios Pharmaceuticals falls -23.7%

2026-04-20T14:34:15.000Z - 25 days ago

Agios sinks after Novo Nordisk reports sickle cell data

NVO

2026-04-06T12:31:27.000Z - 5 weeks ago

Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan

2026-04-06T12:26:47.000Z - 5 weeks ago

Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan

Apr 6, 2026, 7:00 AM EDT - 5 weeks ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

2026-04-01T10:27:47.000Z - 6 weeks ago

Agios Pharmaceuticals price target raised to $32 from $28 at Goldman Sachs

2026-03-31T17:30:41.000Z - 6 weeks ago

Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update

FULC

Mar 31, 2026, 8:45 AM EDT - 6 weeks ago

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

2026-03-31T11:20:18.000Z - 6 weeks ago

Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat

Mar 31, 2026, 7:00 AM EDT - 6 weeks ago

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

2026-03-05T11:46:12.000Z - 2 months ago

Citi ups Agios target, opens ‘upside 90-day catalyst watch’

Mar 2, 2026, 11:50 AM EST - 2 months ago

Agios Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T12:26:31.000Z - 2 months ago

Agios Pharmaceuticals Pyrukynd approved for adults in UAE

Mar 2, 2026, 7:00 AM EST - 2 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

2026-02-12T21:27:36.000Z - 3 months ago

Agios Pharmaceuticals files automatic mixed securities shelf

Feb 12, 2026, 8:00 AM EST - 3 months ago

Agios Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 6:30 AM EST - 3 months ago

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Jan 26, 2026, 7:00 AM EST - 3 months ago

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Jan 14, 2026, 11:15 AM EST - 4 months ago

Agios Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 4 months ago

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Jan 5, 2026, 7:00 AM EST - 4 months ago

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 24, 2025, 9:56 AM EST - 5 months ago

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Dec 24, 2025, 8:22 AM EST - 5 months ago

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

Dec 24, 2025, 8:00 AM EST - 5 months ago

Agios Pharmaceuticals Transcript: FDA Announcement

Dec 23, 2025, 7:45 PM EST - 5 months ago

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Dec 8, 2025, 7:00 AM EST - 5 months ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Nov 19, 2025, 8:24 AM EST - 6 months ago

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Nov 19, 2025, 8:00 AM EST - 6 months ago

Agios Pharmaceuticals Transcript: Study Result

Nov 19, 2025, 7:00 AM EST - 6 months ago

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Nov 3, 2025, 9:01 AM EST - 6 months ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Agios Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 6:30 AM EDT - 7 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 17, 2025, 8:15 AM EDT - 7 months ago

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Oct 17, 2025, 8:00 AM EDT - 7 months ago

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Oct 16, 2025, 7:00 AM EDT - 7 months ago

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Sep 4, 2025, 7:00 AM EDT - 9 months ago

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Aug 4, 2025, 4:01 PM EDT - 10 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Agios Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 6:30 AM EDT - 10 months ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 14, 2025, 7:00 AM EDT - 10 months ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 8, 2025, 7:00 AM EDT - 11 months ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Agios Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 7:00 AM EDT - 1 year ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 21, 2025, 8:00 AM EDT - 1 year ago

Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 11:00 AM EDT - 1 year ago

Agios Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 10:00 AM EDT - 1 year ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 9, 2025, 7:00 AM EDT - 1 year ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 2, 2025, 7:00 AM EDT - 1 year ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Agios Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 6:30 AM EDT - 1 year ago

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Mar 12, 2025, 12:30 PM EDT - 1 year ago

Agios Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 10:40 AM EDT - 1 year ago

Agios Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 5:52 PM EST - 1 year ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Mar 4, 2025, 7:00 AM EST - 1 year ago

Agios to Present at Upcoming Investor Conferences

Mar 3, 2025, 10:30 AM EST - 1 year ago

Agios Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 7:00 AM EST - 1 year ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Agios Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 13, 2025, 6:31 AM EST - 1 year ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 13, 2025, 6:30 AM EST - 1 year ago

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Feb 6, 2025, 7:00 AM EST - 1 year ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Jan 15, 2025, 10:30 AM EST - 1 year ago

Agios Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BIIB

Dkll303 May. 15 at 5:24 PM

0 · Reply

Dkll303 May. 13 at 7:51 PM

0 · Reply

freddie04 May. 12 at 6:05 PM

$AGIO neither one , can create value and the cash is being burned up

0 · Reply

freddie04 May. 12 at 6:04 PM

$AGIO 5 year return from Fouse NEGATIVE 49% …Jackie Fouse is a failure With Brian Goff , right behind her failing as well !!! 2 biotech losers

0 · Reply

freddie04 May. 12 at 5:06 PM

0 · Reply

Dkll303 May. 11 at 6:27 PM

0 · Reply

Dkll303 May. 11 at 2:22 PM

$AGIO back at it again, huh Morgan Stanley !!! Pushing it for the inside …SELLERS

0 · Reply

Dkll303 May. 7 at 11:40 AM

0 · Reply

Dkll303 May. 6 at 5:15 PM

0 · Reply

Dkll303 May. 6 at 5:09 PM

$AGIO misfits still exist here

0 · Reply

Dkll303 May. 6 at 2:18 AM

$AGIO $CADL Read it and weep, this post is no Tabloid News..it is the truth , lol

1 · Reply

IN0V8 May. 4 at 3:08 PM

$AGIO "Q1 2026 saw 138% revenue growth to $20.7M, driven by a strong AQVESME launch in thalassemia and robust U.S. demand. Mitapivat sNDA for sickle cell disease is on track for Q2, and the pipeline remains catalyst-rich with key data readouts expected this year."

0 · Reply

Dkll303 May. 4 at 11:37 AM

$AGIO the name was Chris Bowden. He is also responsible for the drug Mitapivat…another revenue source Sarah G . ..she has got nothing Fouse has got nothing goff is a wind bag..got nothing Guess Bowden was the fruit that kept on giving

0 · Reply

Dkll303 May. 4 at 11:34 AM

$AGIO they aren’t …AGIOS is the laughing stock of wall st

0 · Reply

risingofmars Apr. 30 at 1:37 PM

$AGIO metal

0 · Reply

LibertarianTreehugger Apr. 30 at 12:37 PM

Why Investors Are Suddenly Paying Attention to Agios Pharmaceuticals: https://www.smartinvestornews.com/all-articles/why-investors-are-suddenly-paying-attention-to-agios-pharmaceuticals $AGIO

0 · Reply

freddie04 Apr. 29 at 8:11 PM

$AGIO BFD ..existing management hasn’t found an avenue to turn a profit Only Chris Snowden I’d and he left !!! And they are sucking down on his Brillance

0 · Reply

risingofmars Apr. 29 at 7:59 PM

$AGIO

0 · Reply

risingofmars Apr. 29 at 7:43 PM

$AGIO lets

0 · Reply

Mindmld Apr. 29 at 4:34 PM

$AGIO Has a major gap to fill! Not a lot of resistance until $35. Revenue up from 8.7 mil to 20.7 mil in past year. 137 % increase yoy. Cash, cash equivalents and marketable securities are $1.0 billion

0 · Reply

OpenOutcrier Apr. 29 at 12:35 PM

$AGIO (+5.8% pre) Agios (NASDAQ: AGIO) doubles mitapivat revenue and funds 2026 pipeline catalysts https://ooc.bz/l/100337

0 · Reply

StocktwitsEarnings Apr. 29 at 10:38 AM

$AGIO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.69 down -9.03% YoY • Reported revenue of $20.75M up 137.75% YoY

0 · Reply

Market Cap	1.71B
Revenue (ttm)	54.03M
Net Income (ttm)	-412.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-763.98%
Debt to Equity Ratio	0.00

Volume	211,012
Avg Vol	1,102,724
Day's Range	N/A - N/A
Shares Out	59.47M
Stochastic %K	83%
Beta	0.58
Analysts	Strong Sell
Price Target	$41.12